Previous close | 24.66 |
Open | 24.61 |
Bid | 25.09 x 200 |
Ask | 25.16 x 200 |
Day's range | 24.22 - 25.23 |
52-week range | 13.72 - 33.34 |
Volume | |
Avg. volume | 661,330 |
Market cap | 1.466B |
Beta (5Y monthly) | 2.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics Inc (NASDAQ:PTGX), a biopharmaceutical company, has reported an insider sale according to a recent SEC filing.
Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders might be concerned after seeing the share price drop 10% in...